Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer

RATIONALE: Erlotinib, an antineoplastic agent, is indicated for the treatment of patients with advanced nonsmall cell lung cancer. Most common adverse events are manageable, although more severe ones require dose reduction or discontinuation of erlotinib treatment. PATIENT CONCERNS: We present a cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarnieri, Adriano, Alfonso-Bartolozzi, Belén, Ciufo, Gianfranco, Moreno-Montañés, Javier, Gil-Bazo, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459717/
https://www.ncbi.nlm.nih.gov/pubmed/28562552
http://dx.doi.org/10.1097/MD.0000000000007000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459717/
https://www.ncbi.nlm.nih.gov/pubmed/28562552
http://dx.doi.org/10.1097/MD.0000000000007000

Ejemplares similares